Original from: Genomeweb
Molecular testing company Predicine said on Tuesday that its blood and urine cell-free DNA (cfDNA) assay, PredicineCare, has secured a CE-IVD mark.
The targeted next-generation sequencing (NGS) assay is developed to detect single nucleotide variants (SNVs), insertions and deletions (indels), DNA rearrangements (fusions), and copy number variations (CNVs) in patients diagnosed with cancer, according to the Hayward, California-based company.
Predicine said that the liquid biopsy-based PredicineCare can target 152 genes, including guideline-recommended gene targets that are known to be actionable and linked to available therapies or clinical trials.
With this CE-IVD mark, Predicine said it plans to commercialize PredicineCare in Europe as an in vitrodiagnostic (IVD) test.
"Launching PredicineCare as the first CE-IVD marked product is a significant milestone and aligns with the organization's strategy to provide affordable and accessible molecular testing
Source: Predicine Receives CE-IVD Mark for Blood and Urine Liquid Biopsy Assay
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.